Viatris’s Mylan sues to clear path for a generic Wegovy against Novo patents
On 25 September 2026 Reuters reported that Viatris’s Mylan Pharmaceuticals sued Novo Nordisk in Delaware federal court, seeking a ruling that its proposed generic of the GLP-1 weight-loss drug Wegovy would not infringe a Novo patent on single-dose pen administration. Active-ingredient patents still run to 2032.
Generic maker Viatris (via Mylan Pharmaceuticals) has sued Novo Nordisk in the U.S. District Court for the District of Delaware, asking the court to find that its proposed Wegovy generic would not infringe Novo’s patent covering a method of administering single-dose Wegovy pens for weight loss. Reuters reported the filing, made public on Thursday 25 September 2026. A Novo spokesperson declined to comment on pending litigation; Viatris spokespeople did not immediately respond, Reuters said.
What is — and is not — at stake
Novo earned nearly $31 billion last year from its semaglutide-based weight-loss drugs Wegovy and Ozempic, according to a company report cited by Reuters. Generic versions of those products cannot enter the U.S. market until 2032, when Novo patents covering the active ingredient semaglutide expire. The Mylan suit targets a narrower patent on how single-dose pens are administered, not the compound itself. Novo has previously settled other patent lawsuits over proposed Wegovy and Ozempic generics against Mylan and other makers.
Why it matters for patients and markets
Challenges to secondary patents are a standard path for generic firms seeking earlier clarity before 2032. This case (Mylan Pharmaceuticals Inc. v. Novo Nordisk Inc., No. 1:26-cv-01192) is at an early stage; no court ruling clearing a generic has been issued. This article summarises legal reporting and is not medical advice about switching medicines — discuss prescriptions with a clinician.
Also available in: Саха тылаРусскийEspañol中文Portuguêsالعربية